|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2011-5-3
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling. The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:AngiolilloDominick JDJ,
pubmed-author:AylwardPhilip EPE,
pubmed-author:BhattDeepak LDL,
pubmed-author:ContantCharles FCF,
pubmed-author:DAROH JHJ,
pubmed-author:DudekDariuszD,
pubmed-author:FitzgeraldDesmond JDJ,
pubmed-author:FlatherMarcus DMD,
pubmed-author:GoodmanShaun GSG,
pubmed-author:GotoShinyaS,
pubmed-author:GuettaVictorV,
pubmed-author:MontalescotGillesG,
pubmed-author:O'DonoghueMichelle LML,
pubmed-author:WiviottStephen DSD,
pubmed-author:ZeymerUweU,
pubmed-author:ZiecinaRafalR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1843-53
|
|
pubmed:meshHeading |
pubmed-meshheading:21502577-Acute Coronary Syndrome,
pubmed-meshheading:21502577-Aged,
pubmed-meshheading:21502577-Death, Sudden, Cardiac,
pubmed-meshheading:21502577-Female,
pubmed-meshheading:21502577-Hemorrhage,
pubmed-meshheading:21502577-Humans,
pubmed-meshheading:21502577-Imines,
pubmed-meshheading:21502577-Incidence,
pubmed-meshheading:21502577-Liver Diseases,
pubmed-meshheading:21502577-Male,
pubmed-meshheading:21502577-Middle Aged,
pubmed-meshheading:21502577-Myocardial Infarction,
pubmed-meshheading:21502577-Platelet Aggregation Inhibitors,
pubmed-meshheading:21502577-Pyridines,
pubmed-meshheading:21502577-Receptors, Thrombin,
pubmed-meshheading:21502577-Recurrence,
pubmed-meshheading:21502577-Risk Factors,
pubmed-meshheading:21502577-Stroke
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
|
|
pubmed:affiliation |
Brigham and Women's Hospital, Boston, MA 02115, USA. modonoghue@partners.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
